Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Generic versions of major hepatitis C drugs are apparently very effective.
Scaling up treatment of hepatitis C among gay and bisexual men in the United Kingdom could in half the number of new cases among that populati...
People with non-alcoholic steatohepatitis who lose significant body weight are likely to experience improvements in their disease condition.
Non-alcoholic steatohepatitis (NASH) is associated with a 50 percent greater risk of death than non-alcoholic fatty liver disease (NAFLD).
The diabetes drug Victoza (liraglutide) has apparently eliminated NASH in a significant proportion of those treated in a recent trial.
With a quarter of Americans living with the condition, fatty liver disease is increasingly a cause of liver cancer.
A new immune therapy targeting hepatitis B has shown promise in an animal study.
Knowing your hepatitis C status has no apparent effect on the likelihood of your developing advanced liver fibrosis.
Researchers have identified a new therapy that could help treat liver cancer in a certain subset of people with the disease.
Various combinations of Sovaldi, Olysio and ribavirin can cure hepatitis C among those with decompensated cirrhosis.
An investigational anti-diabetes drug may be an option for treating NASH and NAFLD.
Daclatasvir and Sovaldi, with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatiti...
Daclatasvir and Sovaldi, with or without ribavirin, offer near-perfect hepatitis C cure rates among those who have received a liver transplant...
People with hepatitis C are at increased risk of cardiovascular disease.
A significant proportion of people with undiagnosed hepatitis C likely have advanced liver disease and are in relatively urgent need of treatm...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.